ABSTRACT
Introduction
Osteosarcoma is a highly malignant tumor occurring frequently in children and young adults 1 . Similar to other solid tumors, osteosarcoma often metastasizes to distant organs, especially the lung in early phase 2 . Generally, the metastatic foci are always very small and may not cause symptoms, which makes the diagnosis difficult and leads to poor response to conventional treatments including surgical intervention and aggressive cytotoxic chemotherapy 3, 4 . Pulmonary metastasis is proved to be a major cause of death in patients suffering from osteosarcoma 5 .
However, little is known about the exact mechanism underlying the spontaneous pulmonary metastasis of osteosarcoma. Several factors have been found to be associated with osteosarcoma metastasis in which concomitant tumor resistance (CTR) plays an important role [6] [7] [8] . The CTR is a phenomenon in which a tumorbearing host is resistant to the growth of secondary tumor implants and metastasis via the systemic angiogenic suppression. After primary tumorectomy, the angiogenesis and pulmonary metastasis might be accelerated 9, 10 .
A preliminary report has been published previously in which the relationship between tumorectomy and pulmonary metastasis was investigated 11 . The present study aimed to investigate the effect of primary tumorectomy on angiogenesis and pulmonary metastasis in osteosarcoma-bearing nude mice and to explore the relationship among angiogenesis, pulmonary metastasis and primary tumorectomy. The probable mechanism and implication of CTR was also discussed on the basis of findings in the present study and previous studies.
Methods
This study was carried out in the Tongji University School of Medicine, Shanghai, China. The study was approved and in accordance with the Animal Welfare Regulations of TUMS.
Nude mice (Balb/c, nu/nu) in the present study were purchased from the SLAC Laboratory Animal of Chinese Academy of Science (Shanghai, China). Mice were 5-week-old and had a body weight of 16~20g. They were housed in a specific pathogen-free environment at TUMS. 
Cell culture

Sampling and detection
On days 7, 14 and 21, five mice in each subgroup were anesthetized at each time point and blood (1.0 mL) was obtained. The osteosarcoma-bearing mice (n=20) in TR group received left forelimb amputation to remove the tumor completely, and mice in the SO and UT groups were treated as above-mentioned on day 14. Two weeks later, all mice were anesthetized and the lungs were removed. Mice with macroscopic pulmonary metastasis were recorded, and the incidence of metastasis was calculated individually. Then, pulmonary tissues were fixed in 10%
formaldehyde and prepared for routine histological examination.
Each experiment was performed in triplicate and found to be reproducible.
Statistical analysis
Statistical analysis was performed with SPSS 13.0 (Chicago, IL). Quantitative data were expressed as mean ± standard deviation (SD). One-way analysis of variance was employed to compare the means among groups. The least significant difference (LSD) was used to compare the means between two groups. A value of p<0.05 was considered statistically significant.
Results
After operation, the expression of endostatin and VEGF in the TR group decreased significantly when compared with the other two groups (VEGF: TR: 79.55 ± 7.82 pg/mL vs. SO: 110.01 ± 5.69 pg/mL, UT: 123.50 ± 10.41 pg/mL, p < 0.01; endostatin:
47.09 ± 6.22 ng/mL vs. 117.64 ± 7.39 ng/mL, 126.73 ± 6.55 ng/mL, p < 0.01) (Figures 1 and 2 ). There was no significant difference in the expression of VEGF and endostatin between SO group and UT group on days 7, 14, 21 and 28.
FIGURE 1 -VEGF expression in three groups. The levels of VEGF were relatively stable preoperatively and when the mice were treated non-operatively as well as by sham amputation. The level of VEGF in peripheral circulation was 110.01 ± 5.69 pg/mL and 123.50 ± 10.41 pg/ mL in the SO group and UT group, respectively, after surgery. However, it significantly decreased to 79.55 ± 7.82 pg/mL after tumorectomy (p<0.01). Additionally, in the TR group, 16 mice developed micrometastatic foci in the lung, which were found in only eight mice of SO group and seven mice of UT group. The incidence of pulmonary metastasis was 80.0%, 40.0% and 35.0% in the TR, SO and UT groups, respectively. Histologically, the severity of metastatic foci was higher in the TR group than in other two groups.
The endostatin level was relatively stable preoperatively and when the animals were treated non-operatively as well as by sham amputation. The level of endostatin in peripheral circulation was 117.64 ± 7.39 ng/mL and 126.73 ± 6.55 ng/mL in the SO group and UT group, respectively, after surgery. However, it significantly decreased to 47.09 ± 6.22 ng/mL after tumorectomy (p<0.01). intact. This distinct phenomenon that primary cancer is able to inhibit the growth of micrometastasis is known as CTR 9 .
The exact mechanism of CTR is not well defined;
however, there are several hypotheses to explain this unique phenomenon. Bashford et al. 18 assumed that CTR was induced by immune reaction and called it "concomitant immunity". Several years later, investigators also identified this phenomenon in non-detectable immunogenicity or immunodeficient mice with cancer, and the term "concomitant immunity" was deserted 10, 19 . Based on our findings, we may speculate that it is necessary to consider additional antiangiogenic treatment after primary tumorectomy. The anti-angiogenic therapy represents a new approach to cure osteosarcoma and has several advantages as compared to traditional adjuvant chemotherapy. The antiangiogenic therapy can inhibit the cancer growth through interrupting angiogenesis in cancers, and it is more selective and efficient than conventional chemotherapy. Meanwhile, the novel treatment may reduce the incidence of drug resistance because the target of angiogenic inhibitors is vascular endothelial cells which are genetically stable. It is supposed that favorable outcome might be achieved when anti-angiogenic treatment is applied in combination with neoadjuvant chemotherapy 23 . Kaya et al. 8 found that the angiogenic inhibitor (endostatin) could suppress the pulmonary metastasis of osteosarcoma after primary tumorectomy.
The anti-angiogenic therapy has clinical significance in preventing pulmonary metastasis of osteosarcoma after primary tumorectomy [24] [25] [26] .
